Edwards Lifesciences Corporation Stock

Equities

EW

US28176E1082

Advanced Medical Equipment & Technology

Market Closed - Nyse 04:00:02 2024-04-25 pm EDT 5-day change 1st Jan Change
88.01 USD -0.68% Intraday chart for Edwards Lifesciences Corporation +1.80% +15.42%
Sales 2024 * 6.52B Sales 2025 * 7.15B Capitalization 53.34B
Net income 2024 * 1.62B Net income 2025 * 1.82B EV / Sales 2024 * 7.9 x
Net cash position 2024 * 1.87B Net cash position 2025 * 3.09B EV / Sales 2025 * 7.02 x
P/E ratio 2024 *
33 x
P/E ratio 2025 *
29.5 x
Employees 19,800
Yield 2024 *
-
Yield 2025 *
-
Free-Float 91.59%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.39%
1 week+1.80%
Current month-7.90%
1 month-5.53%
3 months+19.66%
6 months+28.78%
Current year+15.42%
More quotes
1 week
85.38
Extreme 85.38
89.17
1 month
85.38
Extreme 85.38
96.12
Current year
71.67
Extreme 71.67
96.12
1 year
60.57
Extreme 60.57
96.12
3 years
60.57
Extreme 60.57
131.73
5 years
51.51
Extreme 51.5067
131.73
10 years
13.02
Extreme 13.02
131.73
More quotes
Managers TitleAgeSince
Chief Executive Officer 56 14-12-31
Chairman 71 99-12-31
Director of Finance/CFO 57 13-12-31
Members of the board TitleAgeSince
Director/Board Member 63 16-07-04
Director/Board Member 67 14-11-12
Director/Board Member 72 16-03-15
More insiders
Date Price Change Volume
24-04-25 88.01 -0.68% 4 295 021
24-04-24 88.61 +0.98% 3,234,988
24-04-23 87.75 +0.91% 2,663,641
24-04-22 86.96 +1.19% 2,408,082
24-04-19 85.94 -0.59% 3,895,701

Delayed Quote Nyse, April 25, 2024 at 04:00 pm EDT

More quotes
Edwards Lifesciences Corporation specializes in designing, manufacturing and marketing medical systems and devices for treating cardiovascular diseases. Net sales break down by family of products as follows: - heart valves and surgery products (67.9%); - hemodynamic monitoring systems (15.5%); - other (16.6%): balloon catheters, artificial implants, etc. Net sales are distributed geographically as follows: the United States (58.4%), Europe (22.2%), Japan (7.6%) and other (11.8%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
88.61 USD
Average target price
94.48 USD
Spread / Average Target
+6.63%
Consensus